Knowledge Hub · Lu-177 n.c.a.
The starting material that decidesevery Lu-177 labelling yield.
Lu-177 is the workhorse therapeutic β⁻ emitter of contemporary theranostics — PSMA-617 for mCRPC, DOTATATE for NETs, FAPI for tumour-stroma protocols. What separates a good clinical batch from a marginal one is set upstream of the labelling kit: how much cold lutetium is in the matrix, how much Lu-177m metastable contamination tails into long-term organ dose, and how tightly the radionuclidic purity meets the pharmacopoeia. This page unpacks what "no-carrier-added" actually buys.
Why this matters
Six things n.c.a. Lu-177 delivers, explained simply
What "n.c.a." actually means
No cold lutetium competing for the labelling kit
Lu-177 can be produced two ways. Carrier-added production (direct neutron capture on Lu-176 targets) ships a matrix dominated by stable Lu-175/176. n.c.a. production routes the activity through Yb-176 → Yb-177 → Lu-177, then a chemical separation strips the ytterbium parent — leaving a Lu fraction in which essentially every atom is Lu-177. At the labelling bench, the DOTATATE / PSMA / FAPI peptide does not have to compete against bulk cold lutetium for the chelation site.
Based on: Dash A. et al., Production of ¹⁷⁷Lu for targeted radionuclide therapy: a review. Nucl. Med. Biol. 2015.
Read source ↗Specific activity → labelling yield
≥3,000 GBq/mg changes what you can label
Standard carrier-added Lu-177 typically lands around 600 GBq/mg. SHINE Medical n.c.a. ¹⁷⁷LuCl₃ delivers ≥3,000 GBq/mg at calibration with batch peaks near 3,700 GBq/mg. The ratio is roughly 5×. For the same therapeutic activity, n.c.a. lets the radiopharmacist label with five-fold less peptide mass — keeping the patient peptide dose low, the labelling yield high, and the tumour-to-background ratio clean on imaging.
Based on: Specific activity claims sourced to the SHINE FDA Drug Master File summary; benchmarked against EANM PRRT practical guidance.
Read source ↗Lu-177m — the kidney-dose argument
Negligible ¹⁷⁷ᵐLu means waste decays in days, not months
Carrier-added Lu-177 batches carry a metastable Lu-177m impurity (T½ ≈160 days). That long-lived contaminant contributes disproportionately to long-tail kidney dose during therapy and forces a long decay-store dwell for spent vials and patient excreta. n.c.a. production effectively eliminates Lu-177m — the spent-vial waste decays on the primary 6.65-day half-life, which is what the AERB-style decay-store rotation expects.
Based on: IAEA TECDOC-1955 Lu-177 production and quality; AERB Atomic Energy (Radiation Protection) Rules 2004.
Read source ↗208 keV imaging gamma
Built-in post-therapy SPECT/CT dosimetry
Lu-177 emits a 208 keV gamma (11 %) alongside the therapeutic β⁻. That is exactly the energy window a clinical SPECT camera maps for quantitative imaging. After each cycle, post-therapy SPECT/CT yields tumour and organ activity per voxel, feeding the dosimetry workflow EANM and AAPM TG-181 / TG-211 expect. n.c.a. activity per peptide is high enough to deliver clinical activity at low peptide mass — the imaging side stays clean.
Based on: EANM dosimetry guidance for radiopharmaceutical therapies; AAPM TG-181 PET/NM QA.
Read source ↗cGMP + FDA Drug Master File
Upstream regulatory dossier already assembled
SHINE Medical (Janesville, Wisconsin) produces the Lu-177 starting material under cGMP and ICH-Q7, with an FDA Drug Master File on file. For an Indian centre running an AERB-licensed theranostic programme, the upstream radionuclide dossier is already built — Saxsons supplies the AERB import licensing, sealed-source documentation and CDSCO-aligned paperwork on the India side.
Based on: ICH-Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients; FDA 21 CFR.
Read source ↗One n.c.a., three (and counting) targets
Same starting material across DOTATATE, PSMA and FAPI
A centre running PRRT alone today can extend the same SHINE-produced Lu-177 supply chain to PSMA-617 when the prostate clinic comes online, and to FAPI when the pancreatic-stroma protocol gets ethics approval — without re-qualifying the radionuclide. One Saxsons import line, one calibration schedule, three (and counting) clinical programmes downstream.
Based on: Saxsons supply-chain framing; consistent with the SHINE multi-target labelling examples.
Read source ↗Specification snapshot
≥3,000
GBq/mg
Specific activity at calibration
≥99.9 %
Radionuclidic purity
Ph. Eur. compliant
6.65 d
Half-life
β⁻ + 208 keV imaging γ
Negligible
Lu-177m
Spent-vial waste decays in days
Scope of this page
This page covers the upstream n.c.a. Lu-177 starting material. Target-specific knowledge — DOTATATE labelling for NETs, PSMA-617 labelling for mCRPC, FAPI labelling for tumour-stroma protocols — lives on the per-target knowledge hubs linked from the Where Next section. Activity-level claims and specific-activity figures are sourced to the SHINE FDA Drug Master File summary; clinical-protocol claims are sourced to peer-reviewed literature and EANM / AAPM guidelines.
Regulatory + production references
The IAEA, EANM and ICH documents that frame Lu-177 n.c.a. production, labelling and clinical use.
IAEA TECDOC-1955 — Production of Long Lived Parent Radionuclides for Generators
IAEA review of Lu-177 production routes, including the n.c.a. (Yb-176 → Yb-177 → Lu-177) pathway and quality-control expectations.
EANM — Practical guidance on PRRT with Lu-177
European Association of Nuclear Medicine procedural guidelines covering Lu-177 specific-activity, labelling-yield and dosimetry expectations.
ICH-Q7 — GMP for Active Pharmaceutical Ingredients
International Council for Harmonisation GMP guideline that frames upstream Lu-177 manufacturing.
AERB — Atomic Energy (Radiation Protection) Rules 2004
Indian regulatory framework for import, transport, decay-store and disposal of Lu-177 radionuclide consignments.
Literature Radar · auto-updated daily
Latest Lu-177 DOTATATE evidence
Fresh peer-reviewed papers on PRRT for neuroendocrine tumours, auto-updated from Europe PMC.
No papers in the radar yet for this topic. The daily poller will populate it over time —subscribe to the weekly digest and the first matches reach your inbox on the next Monday morning.
Literature Radar · auto-updated daily
Latest Lu-177 PSMA evidence
Fresh peer-reviewed papers on theranostic therapy for mCRPC, auto-updated from Europe PMC.
No papers in the radar yet for this topic. The daily poller will populate it over time —subscribe to the weekly digest and the first matches reach your inbox on the next Monday morning.
Where next